{
    "id": 19434,
    "fullName": "PIK3CA P449T",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA P449T lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). P449T results in increased Pik3ca kinase activity in culture (PMID: 20530683) and therefore, is predicted to result in a gain of Pik3ca protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1863,
                    "pubMedId": 20530683,
                    "title": "Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20530683"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "P449T",
    "createDate": "03/09/2016",
    "updateDate": "09/14/2018",
    "referenceTranscriptCoordinates": {
        "id": 172056,
        "transcript": "NM_006218",
        "gDna": "chr3:g.179210279C>A",
        "cDna": "c.1345C>A",
        "protein": "p.P449T",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4936,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8204,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 4657,
                "therapyName": "Pimasertib + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8189,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 871,
                "therapyName": "Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8199,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 1659,
                "therapyName": "Pimasertib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8194,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 4656,
                "therapyName": "Everolimus + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 337,
                    "pubMedId": 23629727,
                    "title": "Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23629727"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4940,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4950,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).",
            "molecularProfile": {
                "id": 19841,
                "profileName": "BRAF V600E PIK3CA P449T"
            },
            "therapy": {
                "id": 1305,
                "therapyName": "Cetuximab + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4805,
                    "pubMedId": 25838391,
                    "title": "Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25838391"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8565,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).",
            "molecularProfile": {
                "id": 26358,
                "profileName": "BRAF V600E PIK3CA P449T TP53 R273H"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 19840,
            "profileName": "PIK3CA P449T",
            "profileTreatmentApproaches": [
                {
                    "id": 17430,
                    "name": "mTOR Inhibitor",
                    "profileName": "PIK3CA P449T"
                },
                {
                    "id": 17429,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "PIK3CA P449T"
                },
                {
                    "id": 17423,
                    "name": "PIK3CA inhibitor",
                    "profileName": "PIK3CA P449T"
                },
                {
                    "id": 17428,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PIK3CA P449T"
                },
                {
                    "id": 17425,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PIK3CA P449T"
                },
                {
                    "id": 17426,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PIK3CA P449T"
                },
                {
                    "id": 17424,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "PIK3CA P449T"
                },
                {
                    "id": 17427,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PIK3CA P449T"
                }
            ]
        },
        {
            "id": 19841,
            "profileName": "BRAF V600E PIK3CA P449T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26358,
            "profileName": "BRAF V600E PIK3CA P449T TP53 R273H",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 172055,
            "transcript": "XM_006713658",
            "gDna": "chr3:g.179210279C>A",
            "cDna": "c.1345C>A",
            "protein": "p.P449T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 172057,
            "transcript": "XM_011512894",
            "gDna": "chr3:g.179210279C>A",
            "cDna": "c.1345C>A",
            "protein": "p.P449T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 172056,
            "transcript": "NM_006218",
            "gDna": "chr3:g.179210279C>A",
            "cDna": "c.1345C>A",
            "protein": "p.P449T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}